Loading…
← CockpitCompetitor Analysis › 605016.SS Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class AOpen in the cockpit ↗

Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class A605016.SSCompetitor analysis, valuation and peers

China · CNY·Consumer Staples›Food: Specialty/Candy

Chinese maker of functional food ingredients such as dietary fiber, resistant dextrin and prebiotics for food/beverage makers.

≈ A Chinese food-ingredient specialist, akin to a smaller Tate & Lyle/IngredionMomentum neutral 47
Mkt cap
$1.24B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$9.01M
20-day average traded
Fwd P/E
18.4×
forward earnings
ROIC−WACC
+11.2 pp
WACC 7.9%
Hurdle
-14 pp
Req g minus delivered
Next earnings
168 days
23 Apr 2027
Close · CNYCN¥19.68
1D+1.6%
1W+14.1%
1M-2.7%
3M-7.6%
6M-27.6%
YTD-8.9%
1Y+2.3%
ATR %4.0%
52w lowhigh32.4% off high

What Shandong Bailong Chuangyuan Bio-Tech does

Chinese maker of functional food ingredients such as dietary fiber, resistant dextrin and prebiotics for food/beverage makers.

In one line: A Chinese food-ingredient specialist, akin to a smaller Tate & Lyle/Ingredion.

Products and services

  • Resistant dextrin/dietary fiber
  • Prebiotic syrups
  • Specialty sweeteners

Customers

  • Food & beverage manufacturers (domestic & export)

Where it sits in the supply chain

  • Specialty ingredients
  • Functional food ingredients
  • Dietary fiber, prebiotics, sweetener…

What could go right

  • Global demand for sugar-reduction/gut-health ingredients

What could go wrong

  • Customer concentration
  • Raw material cost swings

Moat: narrow (process know-how, customer qualification). Technical know-how in functional fiber production and qualified relationships with F&B makers.

Headquarters: Yucheng, Shandong, China · Employees: 990

Named competitors

Shandong Bailong Chuangyuan Bio-Tech at a glance

Size Shandong Bailong Chuangyuan Bio-Tech (605016.SS) is a China Consumer Staples company (Food: Specialty/Candy) with a market value of $1.24B, the 1918th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.68 on 6 Nov 2026.

Performance Over six months the shares fell 27.6%, against -16.9% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 19.1% over the last twelve months (peer median +7.8%); the operating margin is 31.6% (peer median 8.4%).

Valuation It trades at 18.4× forward earnings against a peer median of 23.9× (9th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.2 points above its cost of capital (7.9% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010011 May 202611 Aug 20266 Nov 2026Peer median 86605016.SS 71
Six months, rebased to 100: Shandong Bailong Chuangyuan Bio-Tech against the median of its 20 peers (local-currency closes).

Shandong Bailong Chuangyuan Bio-Tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.54BCN¥1.38BCN¥1.14BCN¥864MCN¥719M
Revenue growth—+21%+32%+20%—
Gross profitCN¥718MCN¥560MCN¥367MCN¥272MCN¥219M
EBITDAn/aCN¥536MCN¥339MCN¥241MCN¥194M
Net incomeCN¥397MCN¥369MCN¥246MCN¥193MCN¥151M
Free cash flowCN¥9.01M-CN¥157MCN¥28.8M-CN¥109M-CN¥13.5M
Capital expenditureCN¥598MCN¥297MCN¥282MCN¥312MCN¥176M
Total debtCN¥682MCN¥246MCN¥125MCN¥29.6MCN¥12.0M

Quarterly statements and history in the cockpit →

Shandong Bailong Chuangyuan Bio-Tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%-10%0%+10%2602BIKAJI2201ITM600929004990MANORAMA0546CCLFLO6001276030276008660018002815SENEA605016.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×40×60×2602BIKAJI2201ITM600929004990MANORAMA05460336CCL002891FLO603027600866SENEA605016.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%2602BIKAJI2201MANORAMA0336CCLFLO603027001800SENEA605016.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Bailong Chuangyuan Bio-Tech is the large dot.

Shandong Bailong Chuangyuan Bio-Tech competitors and peer comparison

Head to head with its named competitors (605016.SS vs INGR vs TATE.L vs 000930.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Bailong Chuangyuan Bio-Tech 605016.SS$1.24B-28%+19%32%18.4×8.8%
Ingredion INGR$5.78B-15%-1%12%9.7×-7.8%
Tate & Lyle TATE.L$3.34B+53%+16%9%15.2×10.8%
COFCO Biotechnology 000930.SZ$1.32B-21%-9%-2%n/an/a

How Shandong Bailong Chuangyuan Bio-Tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Bailong Chuangyuan Bio-Tech against its 20 peers (data as of 6 Nov 2026)
Measure605016.SSPeer medianRank in peer set
1-month return-2.7%-1.4%9th lowest of 21
6-month return-27.6%-16.9%4th lowest of 20
Distance from 52-week high-32.4%-30.5%11th highest of 21
Revenue growth (TTM)+19.1%+7.8%5th highest of 21
Operating margin31.6%8.4%highest of 21
Forward P/E18.4×23.9×9th cheapest of 18
Growth the price implies (Req g, 7 yrs)8.8%3.1%5th most demanding of 12
Growth delivered (Del g)+22.5%+8.3%3rd highest of 12
Hurdle (Req g minus delivered)-13.7 pp-11.3 pp3rd least demanding of 12
ROIC minus cost of capital+11.2 pp+1.5 pp2nd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Bailong Chuangyuan Bio-Tech 605016.SSChina$1.24B-28%+19%32%18.4×8.8%+22.5%
Nisshin OilliO 2602.TJapan$1.22B+13%+8%3%18.0×3.1%+10.5%
Bikaji Foods International BIKAJI.NSIndia$1.27B-29%+14%10%37.4×38.6%+17.5%
Morinaga & 2201.TJapan$1.28B-8%+3%9%12.3×-5.7%+7.1%
Italmobiliare ITM.MIItaly$1.20B-8%+8%14%12.0×n/an/a
Snowsky Salt Industry 600929.SSChina$1.20B-29%+32%1%54.7×n/an/a
Lotte 004990.KSSouth Korea$1.18B-27%+1%2%69.5×n/an/a
Manorama Industries MANORAMA.NSIndia$1.31B+22%+60%24%39.3×33.4%+46.9%
Fufeng 0546.HKHong Kong$1.31B-37%+1%4%7.4×n/an/a
Huabao International 0336.HKHong Kong$1.34B-25%+13%3%25.3×16.2%-2.7%
CCL Products (India) CCL.NSIndia$1.37B-20%+24%13%25.8×17.9%+29.1%
Yantai China Pet Foods 002891.SZChina$1.39B-15%+21%4%32.6×n/an/a
Jiangxi Qiyunshan Food 2797.HKHong Kong$1.10Bn/a-7%17%n/an/an/a
Flowers Foods FLOUnited States$1.42B-20%+2%6%8.8×-7.6%+3.7%
JinJian Cereals Industry 600127.SSChina$1.08B+64%+1%-1%n/an/an/a
Qianhe Condiment & Food 603027.SSChina$1.43B-21%-6%14%23.9×3.1%+8.8%
Star Lake Bioscience 600866.SSChina$1.07B-26%-3%0%37.2×n/an/a
ORION 001800.KSSouth Korea$1.06B-4%+15%15%n/a-16.5%+8.3%
Chacha Food 002557.SZChina$1.46B-17%+8%8%15.8×n/an/a
ARIAKE JAPAN 2815.TJapan$1.04B-5%+3%17%17.4×-7.4%+6.1%
Seneca Foods SENEAUnited States$1.03B+9%+12%9%10.9×-15.1%+2.5%

Questions

Who are Shandong Bailong Chuangyuan Bio-Tech's main competitors?
Named competitors: Ingredion (INGR), Tate & Lyle (TATE.L), COFCO Biotechnology (000930.SZ). The cockpit's measured peer set (industry) also includes Nisshin OilliO (2602.T), Bikaji Foods International (BIKAJI.NS), Morinaga & (2201.T), Italmobiliare (ITM.MI), Snowsky Salt Industry (600929.SS), Lotte (004990.KS).
Is Shandong Bailong Chuangyuan Bio-Tech expensive compared with its peers?
On forward p/e it trades at 18.4× against a peer median of 23.9×, 9th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Shandong Bailong Chuangyuan Bio-Tech stock performed?
Over six months to 6 Nov 2026 the shares returned -27.6% against -16.9% for the median peer; over one year +2.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.